陈璐 李婧

    [摘要] 心脑血管疾病是一种严重威胁人类健康的常见疾病，居各种死因的首位。其中，胆固醇尤其是低密度脂蛋白胆固醇(LDL-C)与其发病息息相关。目前指南推荐控制LDL-C的首选药物是他汀类药物，但其服用后可出现多种不良反应。人前蛋白转化酶枯草溶菌素9(PCSK9)近年来被发现与LDL-C有密切的相关性，目前已有大量的研究可以证明PCSK9抑制剂可降低血LDL-C水平，甚至有机会应用于降压治疗。本文将系统综述PCSK9抑制剂在高脂血症及高血压中的研究现状。

    [关键词] 低密度脂蛋白胆固醇；高血压；人前蛋白转化酶枯草溶菌素9；人前蛋白转化酶枯草溶菌素9抑制剂

    [中图分类号] R544 [文献标识码] A [文章编号] 1673-7210(2019)04(c)-0042-04

    [Abstract] Cardiovascular and cerebrovascular disease (CVD) is a serious threat to human health. Among them， cholesterol， especially low-density lipoprotein cholesterol (LDL-C)， is closely related to the pathogenesis. The current guidelines recommend statins as the first choice for LDL-C control， Howerer， some data showed that after taking can appear a variety of adverse reactions. In recent years， human proprotein invertase subtilis 9 (PCSK9) has been found to have a close correlation with LDL-C. At present， a large number of studies have proved that PCSK9 inhibitors can reduce the level of LDL-C in blood， and even have the opportunity to be applied in the antihypertensive therapy. In this paper， the research status of PCSK9 inhibitors in hyperlipidemia and hypertension was systematically reviewed. ......